Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country

Abstract

This study compared retrospectively the effectiveness, toxicity and hematopoietic recovery after autologous peripheral blood stem cell transplantation (ASCT) of two consecutive peripheral blood stem cell mobilization regimens in newly diagnosed MM patients. Patients in group 1 (n=178) were treated with 4 g/m of cyclophosphamide (CY) plus G-CSF (5 μg/kg/day). Patients in group 2 (n=117) with 750 mg/m of VP16 plus G-CSF (10 μg/kg/day). Optimal mobilization, defined by a target number of 8 × 10 CD34+ cells/kg collected, was achieved in 62.4% and 89.7% of patients in groups 1 and 2, respectively (P<10). The median number of aphaeresis sessions was reduced from two in group 1 to one in group 2 (P<10). Grade neutropenia, febrile neutropenia and IV antibiotic use were significantly more frequent in group 1 than in group 2 (P<10). Red blood cell transfusion requirements were significantly greater in group 1 (P=0.007). The switch to VP16-G-CSF resulted in a significant reduction of the number of hospitalization days (P<10). Neutrophil and platelet recovery after ASCT occurred on days 11 and 12, respectively, in the two groups with no significant differences. VP+G-CSF allowed liberation of resources in the clinical and aphaeresis departments and demonstrated a better effectiveness-safety profile than CY+G-CSF.

Higher efficacy of oral etoposide for mobilization of peripheral blood stem cells in patients with multiple myeloma

“…Our retrospective analysis of clinical data showed that VP-16-induced chemo-mobilization of a higher yield of CD34 + cells/kg compared with IDCy. The results are in line with other reports 16-24 . However, the mechanism has not been fully elucidated.…”

“…The results are in line with other reports. [16][17][18][19][20][21][22][23][24] However, the mechanism has not been fully elucidated. VP-16 is an inhibitor of topoisomerase 2, which damages DNA.…”